US 2007/0185133 A1Published application

Aminopyrimidine compounds and methods of use

AssigneeAmgen Inc.

InventorsAdrian Smith, Paul Brennan, Frenel DeMorin, Gang Liu, Nick Paras, Daniel Retz, Elizabeth Rainbeau

Life of this patent

Estimating the term…

Abstract

The invention relates to aminopyrimidine compounds useful for treating diseases mediated by polo-like kinase 1 (Plk1). The invention also relates to the therapeutic use of such aminopyrimidine compounds and compositions thereof in treating disease states associated with abnormal cell growth and unwanted cell proliferation.

Claims20

Dependent claims

A compound of Formula I

wherein:
X1 is C—R1 or N;
X2 is CH or N;
Y is O, S, CH(R7), or N(R7);
W is selected from CN,
wherein m is 0 or 1, X3 is CH or N, and Z is CH2 or C(O);
R1 and R2 are each independently selected from the group consisting of H, halo, CN, C1-C6 alkyl which may be interrupted by one or more hetero atoms, —(CR8R9)t(aryl), —(CR8R9)t(heteroaryl), —(CR8R9)t(cycloalkyl), —(CR8R9)t(heterocyclyl), —(CR8R9)tN(R10)(R11), —(CR8R9)tSO2(R10), —(CR8R9)tSO2(N)(R10)(R11), —(CR8R9)tSO2(cycloalkyl), —(CR8R9)tSO(R10), or —(CR8R9)tS(R10), or R1 and R2 together with the carbon atoms to which they are attached join to form a C3-C10 heterocyclic or carbocyclic;
R3 is H, OH, halo, NO2, NH2, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylamino, C2-C6 alkenyl, C2-C6 alkynyl, or an aryl or heteroaryl;
R4, R7, R8, and R9 are independently selected from —H and C1-C6 alkyl;
R5 and R6 are independently selected from —H, C1-C6 alkyl, alkenyl, aryl, heteroaryl, cycloalkyl, or heterocyclyl, or R5 and R6 together with the atoms to which they are linked join to form a 3 to 6-membered carbocyclic or heterocyclic;
R10 and R11 are independently selected from C1-C6 alkyl, aryl, heteroaryl, cycloalkyl, and heterocyclyl;
wherein n is an integer from 1 to 6, and each t is an integer from 0 to 2;
wherein the above alkyl, alkenyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, heterocyclic, and carbocyclic moieties are optionally substituted by 1-3 substituents selected from
alkanoyl,
alkylamine,
amino,
aryl, heteroaryl, cycloalkyl, heterocyclyl,
C1-C6 alkyl, C-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 alkoxy, C1-C6 alkylamine, C1-C6 dialkylamine, C2-C6 alkenyl, or C2-C6 alkynyl, wherein each of which may be interrupted by one or more hetero atoms,
carboxyl,
cyano,
halo,
hydroxy,
nitro,
—N═N—NH2,
—C(O)2—(C1-C6 alkyl), —C(O)2-(aryl), —C(O)2-(heteroaryl), —C(O)2-(cycloalkyl), —C(O)2-(heterocyclyl),
—O—(C1-C6 haloalkyl), —O—(C1-C6 alkyl)aryl, —O—(C1-C6 alkyl)heteroaryl, —O—(C1-C6 alkyl)cycloalkyl, —O—(C1-C6 alkyl)heterocyclyl, —O—(C1-C6 alkyl)amino, —O—(C1-C6 alkyl)alkylamino, —O—(C1-C6 alkyl)dialkylamino, —O-aryl, —O-heteroaryl, —NHC(O)—C1-C6 alkyl), —NHC(O)—(C1-C6 alkylene), —NHC(O)-aryl), —NHC(O)-heteroaryl), —NHC(O)-cycloalkyl), —NHC(O)-(heterocyclyl), —NHC(O)—C1-C6 alkyl)aryl, —NHC(O)—(C1-C6 alkyl)heteroaryl, —NHC(O)—(C1-C6 alkyl)cycloalkyl, —NHC(O)—(C1-C6 alkyl)heterocyclyl, —NHC(O)—(C1-C6 alkyl)amino, —NHC(O)—(C1-C6 alkyl)alkylamine, —NHC(O)—(C1-C6 alkyl)dialkylamine, —NHC(O)—(C1-C6 alkyl)C(O)amino, —NHC(O)—(C1-C6 alkyl)C(O)alkylamine, —NHC(O)—(C1-C6 alkyl)C(O)dialkylamine, —NHC(O)—(C1-C6 alkyl)N(H)—(C1-C6 alkyl)C(O)2—(C1-C6 alkyl), —NHC(O)—(C1-C6 alkyl)S(O)2(C1-C6 alkyl), —NHC(O)—(C1-C6 alkyl)—S—(heterocyclyl), —NHS(O)2—C1-C6 alkyl), —NHS(O)2-(aryl), —NHS(O)2-heteroaryl), —NHS(O)2-(cycloalkyl), —NHS(O)2-(heterocyclyl), —NHS(O)(C1-C6 alkyl), —NHS(O)(aryl), —NHS(O)(heteroaryl), —NHS(O)(cycloalkyl), —NHS(O)(heterocyclyl), —NHS(C1-C6 alkyl), —NHS(aryl), —NHS(heteroaryl), —NHS(cycloalkyl), —NH—S—(heterocyclyl),
wherein each of the above aryl, heteroaryl, cycloalkyl, or heterocyclyl moieties can be further optionally substituted by 1-5 substituents selected from
amino,
C1-C6 alkylamine, C1-C6 dialkylamine,
C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkenyl, C1-C6 hydroxyl, and C1-C6 hydroxyalkyl, each optionally substituted by halo,
cyano,
halo, and
nitro,
or a pharmaceutically acceptable salt, hydrate, or stereoisomer thereof.

31 more elements

A compound of Formula I selected from 1-(2-{4-[5-(2-Azetidin-1-yl-ethoxy)-benzo[b]thiophen-2-yl]-5-bromo-pyrimidin-2-ylamino}-ethyl)-5,5-dimethyl-imidazolidine-2,4-dione;

1-(2-{4-[5-(2-Ethyl-phenylsulfanyl)-thiophen-2-yl]-pyrimidin-2-ylamino}-ethyl)-5,5-dimethyl-imidazolidine-2,4-dione;
1-(2-{4-[5-(2-Isopropylamino-ethoxy)-benzo[b]thiophen-2-yl]-5-trifluoromethyl-pyrimidin-2-ylamino}-ethyl)-5,5-dimethyl-imidazolidine-2,4-dione;
1-(2-{5-(1H-Indol-5-yl)-4-[5-(piperidine-1-sulfonyl)-thiophen-2-yl]-pyrimidin-2-ylamino}-ethyl)-imidazolidin-2-one;
1-(2-{5-(3-Hydroxy-phenyl)-4-[5-(piperidine-1-sulfonyl)-thiophen-2-yl]-pyrimidin-2-ylamino}-ethyl)-imidazolidin-2-one;
1-(2-{5-Bromo-4-[2-(4-fluoro-phenylamino)-thiazol-5-yl]-pyrimidin-2-ylamino}-ethyl)-5,5-dimethyl-imidazolidine-2,4-dione;
1-(2-{5-Bromo-4-[2-(methyl-phenyl-amino)-thiazol-5-yl]-pyrimidin-2-ylamino}-ethyl)-5,5-dimethyl-imidazolidine-2,4-dione;
1-(2-{5-Bromo-4-[5-(2-diethylamino-ethoxy)-benzo[b]thiophen-2-yl]-pyrimidin-2-ylamino}-ethyl)-5,5-dimethyl-imidazolidine-2,4-dione;
1-(2-{5-Bromo-4-[5-(2-dimethylamino-ethoxy)-benzo[b]thiophen-2-yl]-pyrimidin-2-ylamino}-ethyl)-5,5-dimethyl-imidazolidine-2,4-dione;
1-(2-{5-Bromo-4-[5-(2-isopropylamino-ethoxy)-benzo[b]thiophen-2-yl]-pyrimidin-2-ylamino}-ethyl)-5,5-dimethyl-imidazolidine-2,4-dione;
1-(2-{5-Bromo-4-[5-(2-piperidin-1-yl-ethoxy)-benzo[b]thiophen-2-yl]-pyrimidin-2-ylamino}-ethyl)-5,5-dimethyl-imidazolidine-2,4-dione;
1-(2-{5-Bromo-4-[5-(2-pyrrolidin-1-yl-ethoxy)-benzo[b]thiophen-2-yl]-pyrimidin-2-ylamino}-ethyl)-5,5-dimethyl-imidazolidine-2,4-dione;
1-(2-{5-Bromo-4-[5-(4-fluoro-benzenesulfonyl)-thiophen-2-yl]-pyrimidin-2-ylamino}-ethyl)-imidazolidin-2-one;
1-(2-{5-Bromo-4-[5-(4-fluoro-benzyl)-4-(2-hydroxy-ethyl)-thiophen-2-yl]-pyrimidin-2-ylamino}-ethyl)-5,5-dimethyl-imidazolidine-2,4-dione;
1-(2-{5-Bromo-4-[5-(4-fluoro-benzyl)-4-(2-isopropylamino-ethyl)-thiophen-2-yl]-pyrimidin-2-ylamino}-ethyl)-5,5-dimethyl-imidazolidine-2,4-dione;
1-(2-{5-Bromo-4-[5-(4-fluoro-benzyl)-4-(2-piperazin-1-yl-ethyl)-thiophen-2-yl]-pyrimidin-2-ylamino}-ethyl)-5,5-dimethyl-imidazolidine-2,4-dione;
1-(2-{5-Bromo-4-[5-(4-fluoro-benzyl)-4-(2-piperidin-1-yl-ethyl)-thiophen-2-yl]-pyrimidin-2-ylamino}-ethyl)-5,5-dimethyl-imidazolidine-2,4-dione;
1-(2-{5-Bromo-4-[5-(4-fluoro-benzyl)-4-(2-pyrrolidin-1-yl-ethyl)-thiophen-2-yl]-pyrimidin-2-ylamino}-ethyl)-5,5-dimethyl-imidazolidine-2,4-dione;
1-(2-{5-Bromo-4-[5-(4-fluoro-benzyl)-thiazol-2-yl]-pyrimidin-2-ylamino}-ethyl)-5,5-dimethyl-imidazolidine-2,4-dione;
1-(2-{5-Bromo-4-[5-(pyrrolidin-2-ylmethoxy)-benzo[b]thiophen-2-yl]-pyrimidin-2-ylamino}-ethyl)-5,5-dimethyl-imidazolidine-2,4-dione;
1-(2-{5-Chloro-4-[2-(methyl-phenyl-amino)-thiazol-5-yl]-pyrimidin-2-ylamino}-ethyl)-5,5-dimethyl-imidazolidine-2,4-dione;
1-(2-{5-Chloro-4-[5-(4-fluoro-benzyl)-4-(2-morpholin-4-yl-ethyl)-thiophen-2-yl]-pyrimidin-2-ylamino}-ethyl)-5,5-dimethyl-imidazolidine-2,4-dione;
1-(2-{5-Chloro-4-[5-(4-fluoro-phenylimino)-4-methyl-4,5-dihydro-[1,3,4]thiadiazol-2-yl]-pyrimidin-2-ylamino}-ethyl)-5,5-dimethyl-imidazolidine-2,4-dione;
1-(2-{5-Chloro-4-[5-(4-methoxy-phenylamino)-[1,3,4]thiadiazol-2-yl]-pyrimidin-2-ylamino}-ethyl)-5,5-dimethyl-imidazolidine-2,4-dione;
1-(2-{5-Fluoro-4-[2-(4-fluoro-phenylamino)-thiazol-5-yl]-pyrimidin-2-ylamino}-ethyl)-5,5-dimethyl-imidazolidine-2,4-dione;
1-(2-{5-Fluoro-4-[2-(methyl-phenyl-amino)-thiazol-5-yl]-pyrimidin-2-ylamino}-ethyl)-5,5-dimethyl-imidazolidine-2,4-dione;
1-(2-{5-Fluoro-4-[5-(2-isopropylamino-ethoxy)-benzo[b]thiophen-2-yl]-pyrimidin-2-ylamino}-ethyl)-5,5-dimethyl-imidazolidine-2,4-dione;
1-(2-{5-Fluoro-4-[5-(4-fluoro-benzyl)-thiazol-2-yl]-pyrimidin-2-ylamino}-ethyl)-5,5-dimethyl-imidazolidine-2,4-dione;
1-[2-(5-Bromo-4-{2-[1-(4-fluoro-phenyl)-ethyl]-thiazol-5-yl}-pyrimidin-2-ylamino)-ethyl]-5,5-dimethyl-imidazolidine-2,4-dione;
1-[2-(5-Bromo-4-{5-(4-fluoro-benzyl)-4-[2-(2-hydroxymethyl-pyrrolidin-1-yl)-ethyl]-thiophen-2-yl}-pyrimidin-2-ylamino)-ethyl]-5,5-dimethyl-imidazolidine-2,4-dione;
1-[2-(5-Bromo-4-{5-(4-fluoro-benzyl)-4-[2-(4-methyl-piperazin-1-yl)-ethyl]-thiophen-2-yl}-pyrimidin-2-ylamino)-ethyl]-5,5-dimethyl-imidazolidine-2,4-dione;
1-[2-(5-Bromo-4-{5-[(4-fluoro-phenyl)-hydroxy-methyl]-thiazol-2-yl }-pyrimidin-2-ylamino)-ethyl]-5,5-dimethyl-imidazolidine-2,4-dione;
1-[2-(5-Bromo-4-{5-[2-(2-methyl-pyrrolidin-1-yl)-ethoxy]-benzo[b]thiophen-2-yl}-pyrimidin-2-ylamino)-ethyl]-5,5-dimethyl-imidazolidine-2,4-dione;
1-[2-(5-Bromo-4-{5-[2-(3-hydroxy-pyrrolidin-1-yl)-ethoxy]-benzo[b]thiophen-2-yl}-pyrimidin-2-ylamino)-ethyl]-5,5-dimethyl-imidazolidine-2,4-dione;
1-[2-(5-Bromo-4-{5-[2-(4-methyl-piperazin-1-yl)-ethoxy]-benzo[b]thiophen-2-yl}-pyrimidin-2-ylamino)-ethyl]-5,5-dimethyl-imidazolidine-2,4-dione;
1-[2-(5-Bromo-4-{5-[2-(isopropyl-methyl-amino)-ethoxy]-benzo[b]thiophen-2-yl}-pyrimidin-2-ylamino)-ethyl]-5,5-dimethyl-imidazolidine-2,4-dione;
1-[2-(5-Chloro-4-{5-[(4-fluoro-phenyl)-methyl-amino]-[1,3,4]thiadiazol-2-yl}-pyrimidin-2-ylamino)-ethyl]-5,5-dimethyl-imidazolidine-2,4-dione;
1-[2-(5-Fluoro-4-{2-[(4-fluoro-phenyl)-(2-pyrrolidin-1-yl-ethyl)-amino]-thiazol-5-yl}-pyrimidin-2-ylamino)-ethyl]-5,5-dimethyl-imidazolidine-2,4-dione;
1-[2-(5-Fluoro-4-{2-[(4-fluoro-phenyl)-(3-hydroxy-propyl)-amino]-thiazol-5-yl}-pyrimidin-2-ylamino)-ethyl]5,5-dimethyl-imidazolidine-2,4-dione;
1-[2-(5-Fluoro-4-{2-[(4-fluoro-phenyl)-(3-morpholin-4-yl-propyl)-amino]-thiazol-5-yl}-pyrimidin-2-ylamino)-ethyl]-5,5-dimethyl-imidazolidine-2,4-dione;
1-[2-(5-Fluoro-4-{2-[(4-fluoro-phenyl)-methyl-amino]-thiazol-5-yl}-pyrimidin-2-ylamino)-ethyl]-5,5-dimethyl-imidazolidine-2,4-dione;
1-[2-(5-Fluoro-4-{5-[(4-fluoro-phenyl)-methyl-amino]-thiazol-2-yl}-pyrimidin-2-ylamino)-ethyl]-5,5-dimethyl-imidazolidine-2,4-dione;
1-{2-[4-(5-Amino-benzo[b]thiophen-2-yl)-5-bromo-pyrimidin-2-ylamino]-ethyl}-5,5-dimethyl-imidazolidine-2,4-dione;
1-{2-[4-(5-Benzenesulfonyl-thiophen-2-yl)-5-bromo-pyrimidin-2-ylamino]-ethyl}-imidazolidin-2-one;
1-{2-[4-(5-Benzyl-[1,3,4]thiadiazol-2-yl)-5-chloro-pyrimidin-2-ylamino]-ethyl}-5,5-dimethyl-imidazolidine-2,4-dione;
1-{2-[4-(5-Benzyl-thiophen-2-yl)-5-bromo-pyrimidin-2-ylamino]-ethyl}-5,5-dimethyl-imidazolidine-2,4-dione;
1-{2-[4-(5-Benzyl-thiophen-2-yl)-pyrimidin-2-ylamino]-ethyl}-5,5-dimethyl-imidazolidine-2,4-dione;
1-{2-[4-[5-(3-Fluoro-benzenesulfonyl)-thiophen-2-yl]-5-(3-hydroxy-phenyl)-pyrimidin-2-ylamino]-ethyl}-5,5-dimethyl-imidazolidine-2,4-dione;
1-{2-[4-[5-(4-Fluoro-benzenesulfonyl)-thiophen-2-yl]-5-(3-hydroxy-phenyl)-pyrimidin-2-ylamino]-ethyl}-5,5-dimethyl-imidazolidine-2,4-dione;
1-{2-[5-Bromo-4-(5-(4-fluoro-benzyl)-4-{2-[2-(isopropylamino-methyl)-pyrrolidin-1-yl]-ethyl}-thiophen-2-yl)-pyrimidin-2-ylamino]-ethyl}-5,5-dimethyl-imidazolidine-2,4-dione;
1-{2-[5-Bromo-4-(7-phenyl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-2-yl)-pyrimidin-2-ylamino]-ethyl}-5,5-dimethyl-imidazolidine-2,4-dione;
1-{2-[5-Chloro-4-(7-phenyl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-2-yl)-pyrimidin-2-ylamino]-ethyl}-5,5-dimethyl-imidazolidine-2,4-dione;
2-[2-(5,5-Dimethyl-2,4-dioxo-imidazolidin-1-yl)-ethylamino]-4-(5-iodo-thiophen-2-yl)-pyrimidine-5-carbonitrile;
5,5-Dimethyl-1-(2-{4-[5-(2-pyrrolidin-1-yl-ethoxy)-benzo[b]thiophen-2-yl]-5-trifluoromethyl-pyrimidin-2-ylaminol}-ethyl)-imidazolidine-2,4-dione;
5,5-Dimethyl-1-{2-[4-(2-phenylsulfanyl-thiazol-5-yl)-pyrimidin-2-ylamino]-ethyl}-imidazolidine-2,4-dione;
5,5-Dimethyl-1-{2-[4-(5-phenylsulfanyl-thiophen-2-yl)-pyrimidin-2-ylamino]-ethyl}-imidazolidine-2,4-dione;
N-(2-{2-[2-(5,5-Dimethyl-2,4-dioxo-imidazolidin-1-yl)-ethylamino]-pyrimidin-4-yl}-benzo[b]thiophen-5-yl)-2-pyridin-3-yl-acetamide

53 more elements

Dependencies are inferred from the claim text.

Facts

Application: 11/304,901Filed 16 Dec 2005
Priority: 17 Dec 2004
Published: 9 Aug 2007
Term ends: Not estimatedThe source records don’t support an estimate.

Classification7 codes

C07D 417/14
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms,…
A61P 19/02
Drugs for skeletal disorders: for joint disorders, e.g. arthritis, arthrosis
A61P 35/00
Antineoplastic agents
A61P 43/00
Drugs for specific purposes, not provided for in groups a61p1/00-a61p41/00

Family

Application60/636,604Us provisional application · filed 17 Dec 2004
US 7,786,132 B2Related patent
US 2007/0185133 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

Abstract

A compound of Formula I

wherein:
X1 is C—R1 or N;
X2 is CH or N;
Y is O, S, CH(R7), or N(R7);
W is selected from CN,
wherein m is 0 or 1, X3 is CH or N, and Z is CH2 or C(O);
R1 and R2 are each independently selected from the group consisting of H, halo, CN, C1-C6 alkyl which may be interrupted by one or more hetero atoms, —(CR8R9)t(aryl), —(CR8R9)t(heteroaryl), —(CR8R9)t(cycloalkyl), —(CR8R9)t(heterocyclyl), —(CR8R9)tN(R10)(R11), —(CR8R9)tSO2(R10), —(CR8R9)tSO2(N)(R10)(R11), —(CR8R9)tSO2(cycloalkyl), —(CR8R9)tSO(R10), or —(CR8R9)tS(R10), or R1 and R2 together with the carbon atoms to which they are attached join to form a C3-C10 heterocyclic or carbocyclic;
R3 is H, OH, halo, NO2, NH2, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylamino, C2-C6 alkenyl, C2-C6 alkynyl, or an aryl or heteroaryl;
R4, R7, R8, and R9 are independently selected from —H and C1-C6 alkyl;
R5 and R6 are independently selected from —H, C1-C6 alkyl, alkenyl, aryl, heteroaryl, cycloalkyl, or heterocyclyl, or R5 and R6 together with the atoms to which they are linked join to form a 3 to 6-membered carbocyclic or heterocyclic;
R10 and R11 are independently selected from C1-C6 alkyl, aryl, heteroaryl, cycloalkyl, and heterocyclyl;
wherein n is an integer from 1 to 6, and each t is an integer from 0 to 2;
wherein the above alkyl, alkenyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, heterocyclic, and carbocyclic moieties are optionally substituted by 1-3 substituents selected from
alkanoyl,
alkylamine,
amino,
aryl, heteroaryl, cycloalkyl, heterocyclyl,
C1-C6 alkyl, C-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 alkoxy, C1-C6 alkylamine, C1-C6 dialkylamine, C2-C6 alkenyl, or C2-C6 alkynyl, wherein each of which may be interrupted by one or more hetero atoms,
carboxyl,
cyano,
halo,
hydroxy,
nitro,
—N═N—NH2,
—C(O)2—(C1-C6 alkyl), —C(O)2-(aryl), —C(O)2-(heteroaryl), —C(O)2-(cycloalkyl), —C(O)2-(heterocyclyl),
—O—(C1-C6 haloalkyl), —O—(C1-C6 alkyl)aryl, —O—(C1-C6 alkyl)heteroaryl, —O—(C1-C6 alkyl)cycloalkyl, —O—(C1-C6 alkyl)heterocyclyl, —O—(C1-C6 alkyl)amino, —O—(C1-C6 alkyl)alkylamino, —O—(C1-C6 alkyl)dialkylamino, —O-aryl, —O-heteroaryl, —NHC(O)—C1-C6 alkyl), —NHC(O)—(C1-C6 alkylene), —NHC(O)-aryl), —NHC(O)-heteroaryl), —NHC(O)-cycloalkyl), —NHC(O)-(heterocyclyl), —NHC(O)—C1-C6 alkyl)aryl, —NHC(O)—(C1-C6 alkyl)heteroaryl, —NHC(O)—(C1-C6 alkyl)cycloalkyl, —NHC(O)—(C1-C6 alkyl)heterocyclyl, —NHC(O)—(C1-C6 alkyl)amino, —NHC(O)—(C1-C6 alkyl)alkylamine, —NHC(O)—(C1-C6 alkyl)dialkylamine, —NHC(O)—(C1-C6 alkyl)C(O)amino, —NHC(O)—(C1-C6 alkyl)C(O)alkylamine, —NHC(O)—(C1-C6 alkyl)C(O)dialkylamine, —NHC(O)—(C1-C6 alkyl)N(H)—(C1-C6 alkyl)C(O)2—(C1-C6 alkyl), —NHC(O)—(C1-C6 alkyl)S(O)2(C1-C6 alkyl), —NHC(O)—(C1-C6 alkyl)—S—(heterocyclyl), —NHS(O)2—C1-C6 alkyl), —NHS(O)2-(aryl), —NHS(O)2-heteroaryl), —NHS(O)2-(cycloalkyl), —NHS(O)2-(heterocyclyl), —NHS(O)(C1-C6 alkyl), —NHS(O)(aryl), —NHS(O)(heteroaryl), —NHS(O)(cycloalkyl), —NHS(O)(heterocyclyl), —NHS(C1-C6 alkyl), —NHS(aryl), —NHS(heteroaryl), —NHS(cycloalkyl), —NH—S—(heterocyclyl),
wherein each of the above aryl, heteroaryl, cycloalkyl, or heterocyclyl moieties can be further optionally substituted by 1-5 substituents selected from
amino,
C1-C6 alkylamine, C1-C6 dialkylamine,
C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkenyl, C1-C6 hydroxyl, and C1-C6 hydroxyalkyl, each optionally substituted by halo,
cyano,
halo, and
nitro,
or a pharmaceutically acceptable salt, hydrate, or stereoisomer thereof.

31 more elements

Facts

Application

11/304,901Filed 16 Dec 2005

Priority

17 Dec 2004

Published

9 Aug 2007

Term ends

Not estimatedThe source records don’t support an estimate.

Classification7 codes

C07D 417/14
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms,…
A61P 19/02
Drugs for skeletal disorders: for joint disorders, e.g. arthritis, arthrosis
A61P 35/00
Antineoplastic agents
A61P 43/00
Drugs for specific purposes, not provided for in groups a61p1/00-a61p41/00